{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:32:53Z","timestamp":1792791173092,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R340-A19380"],"award-info":[{"award-number":["R340-A19380"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R281-A16566"],"award-info":[{"award-number":["R281-A16566"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","award":["00018310"],"award-info":[{"award-number":["00018310"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","award":["00018310"],"award-info":[{"award-number":["00018310"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH core","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"MSKCC bladder SPORE","award":["CA221745"],"award-info":[{"award-number":["CA221745"]}]},{"name":"National Cancer Institute","award":["R01CA272657"],"award-info":[{"award-number":["R01CA272657"]}]},{"name":"National Research Development and Innovation Office Hungary","award":["FK142835"],"award-info":[{"award-number":["FK142835"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"The National Cancer Institute","doi-asserted-by":"crossref","award":["R15 CA 235436-01"],"award-info":[{"award-number":["R15 CA 235436-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research and Technology Innovation Fund","award":["KTIA_NAP_13-2014-0021"],"award-info":[{"award-number":["KTIA_NAP_13-2014-0021"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","award":["BCRF-21-159"],"award-info":[{"award-number":["BCRF-21-159"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant","award":["NNF15OC0016584"],"award-info":[{"award-number":["NNF15OC0016584"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Defense through the Prostate Cancer Research Program","award":["W81XWH-18-2-0056"],"award-info":[{"award-number":["W81XWH-18-2-0056"]}]},{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["7016-00345B"],"award-info":[{"award-number":["7016-00345B"]}],"id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Due to a demonstrated lack of DNA repair deficiencies, clear cell renal cell carcinoma (ccRCC) has not benefitted from targeted synthetic lethality-based therapies. We investigated whether nucleotide excision repair (NER) deficiency is present in an identifiable subset of ccRCC cases that would render those tumors sensitive to therapy targeting this specific DNA repair pathway aberration. We used functional assays that detect UV-induced 6\u20134 pyrimidine-pyrimidone photoproducts to quantify NER deficiency in ccRCC cell lines. We also measured sensitivity to irofulven, an experimental cancer therapeutic agent that specifically targets cells with inactivated transcription-coupled nucleotide excision repair (TC-NER). In order to detect NER deficiency in clinical biopsies, we assessed whole exome sequencing data for the presence of an NER deficiency associated mutational signature previously identified in ERCC2 mutant bladder cancer. Functional assays showed NER deficiency in ccRCC cells. Some cell lines showed irofulven sensitivity at a concentration that is well tolerated by patients. Prostaglandin reductase 1 (PTGR1), which activates irofulven, was also associated with this sensitivity. Next generation sequencing data of the cell lines showed NER deficiency-associated mutational signatures. A significant subset of ccRCC patients had the same signature and high PTGR1 expression. ccRCC cell line-based analysis showed that NER deficiency is likely present in this cancer type. Approximately 10% of ccRCC patients in the TCGA cohort showed mutational signatures consistent with\n                    <jats:italic>ERCC2<\/jats:italic>\n                    inactivation associated NER deficiency and also substantial levels of\n                    <jats:italic>PTGR1<\/jats:italic>\n                    expression. These patients may be responsive to irofulven, a previously abandoned anticancer agent that has minimal activity in NER-proficient cells.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-47946-4","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T06:09:43Z","timestamp":1700719783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Aurel","family":"Prosz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Tisza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Topka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Klus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"B\u00f6rcs\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Sztupinszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Diossy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vizkeleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag Rune","family":"Stormoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Csabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle","family":"Pappot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Vijai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilay","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandor","family":"Spisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailja","family":"Pathania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szallasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"47946_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard, A. M. et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res. 3, 9 (2015).","journal-title":"Biomark. Res."},{"key":"47946_CR2","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1158\/0008-5472.CAN-21-0628","volume":"81","author":"RM Chabanon","year":"2021","unstructured":"Chabanon, R. M. et al. PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer. Cancer Res. 81, 2888\u20132902 (2021).","journal-title":"Cancer Res."},{"key":"47946_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn, J. A., Lans, H., Vermeulen, W. & Hoeijmakers, J. H. J. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell Biol. 15, 465\u2013481 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"47946_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin Cancer Res."},{"key":"47946_CR5","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov."},{"key":"47946_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.102697","volume":"82","author":"AS Rajkumar-Calkins","year":"2019","unstructured":"Rajkumar-Calkins, A. S. et al. Functional profiling of nucleotide excision repair in breast cancer. DNA Repair (Amst) 82, 102697 (2019).","journal-title":"DNA Repair (Amst)"},{"key":"47946_CR7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-16-0487","volume":"6","author":"J Vijai","year":"2016","unstructured":"Vijai, J. et al. A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer Discov. 6, 1267\u20131275 (2016).","journal-title":"Cancer Discov."},{"key":"47946_CR8","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.18632\/oncotarget.13918","volume":"8","author":"EA Kautto","year":"2017","unstructured":"Kautto, E. A. et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget. 8, 7452\u20137463 (2017).","journal-title":"Oncotarget."},{"key":"47946_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94\u2013101 (2020).","journal-title":"Nature"},{"key":"47946_CR10","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-20-3316","volume":"27","author":"J B\u00f6rcs\u00f6k","year":"2021","unstructured":"B\u00f6rcs\u00f6k, J. et al. Identification of a synthetic lethal relationship between nucleotide excision repair deficiency and irofulven sensitivity in urothelial cancer. Clin. Cancer Res. 27, 2011\u20132022 (2021).","journal-title":"Clin. Cancer Res."},{"key":"47946_CR11","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1101\/gr.230219.117","volume":"28","author":"A Boot","year":"2018","unstructured":"Boot, A. et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Res. 28, 654\u2013665 (2018).","journal-title":"Genome Res."},{"key":"47946_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1568-7864(02)00166-0","volume":"1","author":"NGJ Jaspers","year":"2002","unstructured":"Jaspers, N. G. J. et al. Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst) 1, 1027\u20131038 (2002).","journal-title":"DNA Repair (Amst)"},{"key":"47946_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12859-021-04040-8","volume":"22","author":"U Kathad","year":"2021","unstructured":"Kathad, U. et al. A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications. BMC Bioinform. 22, 102 (2021).","journal-title":"BMC Bioinform."},{"key":"47946_CR14","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-03-0349","volume":"10","author":"J Alexandre","year":"2004","unstructured":"Alexandre, J. et al. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin. Cancer Res. 10, 3377\u20133385 (2004).","journal-title":"Clin. Cancer Res."},{"key":"47946_CR15","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1074\/jbc.M706257200","volume":"283","author":"R Rouget","year":"2008","unstructured":"Rouget, R., Auclair, Y., Loignon, M., Affar, E. B. & Drobetsky, E. A. A sensitive flow cytometry-based nucleotide excision repair assay unexpectedly reveals that mitogen-activated protein kinase signaling does not regulate the removal of UV-induced DNA damage in human cells. J. Biol. Chem. 283, 5533\u20135541 (2008).","journal-title":"J. Biol. Chem."},{"key":"47946_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/jpet.112.195768","volume":"343","author":"X Yu","year":"2012","unstructured":"Yu, X. et al. Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. J. Pharmacol. Exp. Ther. 343, 426\u2013433 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"47946_CR17","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-20-3322","volume":"27","author":"S Topka","year":"2020","unstructured":"Topka, S. et al. Targeting germline and tumor associated nucleotide excision repair defects in cancer. Clin. Cancer Res. 27, 1997 (2020).","journal-title":"Clin. Cancer Res."},{"key":"47946_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114024119","volume":"119","author":"A Boot","year":"2022","unstructured":"Boot, A. et al. Recurrent mutations in topoisomerase II\u03b1 cause a previously undescribed mutator phenotype in human cancers. Proc. Natl. Acad. Sci. USA 119, e2114024119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"47946_CR19","first-page":"279","volume":"57","author":"JR MacDonald","year":"1997","unstructured":"MacDonald, J. R. et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res. 57, 279\u2013283 (1997).","journal-title":"Cancer Res."},{"key":"47946_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/IGC.0b013e3181e8df36","volume":"20","author":"RJ Schilder","year":"2010","unstructured":"Schilder, R. J. et al. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial. Int. J. Gynecol. Cancer 20, 1137\u20131141 (2010).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"47946_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.coc.0000139019.17349.ed","volume":"28","author":"N Senzer","year":"2005","unstructured":"Senzer, N. et al. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial. Am. J. Clin. Oncol. 28, 36\u201342 (2005).","journal-title":"Am. J. Clin. Oncol."},{"key":"47946_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ygyno.2005.09.036","volume":"101","author":"MV Seiden","year":"2006","unstructured":"Seiden, M. V. et al. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol. Oncol. 101, 55\u201361 (2006).","journal-title":"Gynecol. Oncol."},{"key":"47946_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1010609810517","volume":"19","author":"WJ Berg","year":"2001","unstructured":"Berg, W. J., Schwartz, L., Yu, R., Mazumdar, M. & Motzer, R. J. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest. New Drugs. 19, 317\u2013320 (2001).","journal-title":"Invest. New Drugs."},{"key":"47946_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10637-005-5055-6","volume":"24","author":"W Hilgers","year":"2006","unstructured":"Hilgers, W. et al. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest. New Drugs. 24, 311\u2013319 (2006).","journal-title":"Invest. New Drugs."},{"key":"47946_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdf008","volume":"13","author":"CM George","year":"2002","unstructured":"George, C. M. et al. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann. Oncol. 13, 116\u2013120 (2002).","journal-title":"Ann. Oncol."},{"key":"47946_CR26","first-page":"1557","volume":"63","author":"AH Rossof","year":"1979","unstructured":"Rossof, A. H. et al. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest oncology group study. Cancer Treat. Rep. 63, 1557\u20131564 (1979).","journal-title":"Cancer Treat. Rep."},{"key":"47946_CR27","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1074\/jbc.271.5.2844","volume":"271","author":"T Yokomizo","year":"1996","unstructured":"Yokomizo, T. et al. cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem. 271, 2844\u20132850 (1996).","journal-title":"J. Biol. Chem."},{"key":"47946_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/nar\/gkp1072","volume":"38","author":"HR Rezvani","year":"2010","unstructured":"Rezvani, H. R. et al. Hypoxia-inducible factor-1alpha regulates the expression of nucleotide excision repair proteins in keratinocytes. Nucleic Acids Res. 38, 797\u2013809 (2010).","journal-title":"Nucleic Acids Res."},{"key":"47946_CR29","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","volume":"28","author":"PJ Hoskin","year":"2010","unstructured":"Hoskin, P. J., Rojas, A. M., Bentzen, S. M. & Saunders, M. I. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J. Clin. Oncol. 28, 4912\u20134918 (2010).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47946-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47946-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T06:20:44Z","timestamp":1700720444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47946-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47946"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47946-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.07.527498","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.W.M\u2014Consulting or Advisory Role: EMD Serono, Pfizer. Research Funding: Pfizer. Patents: Institutional patents filed on <i>ERCC2<\/i> mutations and chemotherapy response (KW.M, Z.S., J.B, Zs. Sz. and M.D.). JV, ST and KO are inventors on a patent application for use of Illudin class of alkylating agents in patients harboring mutations in the <i>ERCC3<\/i> gene (PCT\/US2018\/022588). D.R.S: Research Funding: Pfizer, EMD Serono.H.P.: Research funding from Pfizer and Merck Z.S: Research funding from Lantern Pharma Inc.. Other authors do not have competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20567"}}